The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement

Ocular Immunology and Inflammation

Volumn 12, Issue 1, 2004, Pages 53-58

  Bardak, Yavuz ^a,b   Aridoǧan, Buket Cicioǧlu ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Beh et's disease; Complements; Immunoglobulins; Interleukins

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CONVALESCENCE; DISEASE ACTIVITY; EYE DISEASE; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; UVEITIS;

ADULT; ANTIBODY FORMATION; BEHCET SYNDROME; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULINS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 12144285748     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.1076/ocii.12.1.53.28062     Document Type: Article

References (26)

1. r Shimizu T, Erlich GE, Inaba G, Hayashi K. Behçet's disease (Behçet's syndrome). Semin Arthritis Rheum. 1979;8:223-260.
2. Demiroglu H, Dundar S. Effects of age, sex, and initial presentation on the clinical course of Behçet's syndrome. South Med J. 1997;90: 567.
3. Davatchi F, Baygan F, Chams H, Chams C. Cyclophosphamide in the treatment of the ocular manifestations of Behçet's disease. J Rheumatol. 1984;11:404-405.
4. Benezra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol. 1986;70: 589-592.
5. Demiroglu H, Barista I, Dundar S. Risk factor assessment and prognosis of eye involvement in Behçet's disease in Turkey. Ophthalmology. 1997;104:701-705.
6. Michelson JB, Chisiari FV. Behçet's disease. Surv Ophthalmol. 1984;26: 190-203.
7. Demiroglu H, Barista I, Dundar S. Assessing the risk of deep vein thrombosis in Behçet's disease. Thromb Res. 1996;84:297-298.
8. Orem A, Deger O, Memis O, Bahadir S, Ovali E, Cimsit G. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease. Ann Rheum Dis. 1995;54:726-729.
9. Demiroglu H, Yalcin S, Buyukasik Y, Ozcebe OI, Dundar S. Elevated erythrocyte aggregation as an indicator for an aggressive clinical course in Behçet's disease: a prospective study. Ann Rheum Dis. 1998;57:694-696.
10. Sakane T. New perspective on Behçet's disease. Int Rev Immunol. 1997;14:89-96.
11. Taylor PV, Chamberlain MA, Scott JS. Autoreactivity in patients with Behçet's disease. Br J Rheumatol. 1993;32:908-910.
12. Inoue C, Itoh R, Kawa Y, Mizoguchi M. Pathogenesis of mucocutaneous lesions in Behçet's disease. J Dermatol. 1994;21:474-480.
13. Evereklioglu C, Er H, Türköz Y, Cekmen M. Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediat Inflam. 2002;11:87-93.
14. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335:1078-1080.
15. Yokota K, Oguma K. IgA protease produced by Streptococcus sanguis and antibody production against IgA protease in patients with Behçet's disease. Microbiol Immunol. 1997:41;925-931.
16. Mullaney J, Collum LM. Ocular vasculitis in Behçet's disease: a pathological and immunohistochemical study. Int Ophthalmol. 1985;7:183-191.
17. Kurohara K, Matsui M, Kuroda Y. An immunopathological study during steroid-responsive and steroid-nonresponsive stages on a patient with neuro-Behçet's disease. Rinsho Shinkeigaku. 1993;33: 455-458.
18. Tasci B, Direskeneli H, Serdaroglu P, Akman-Demir G, Eraksoy M, Saruhan-Direskeneli G. Humoral immune response to mycobacterial heat shock protein (hsp)65 in the cerebrospinal fluid of neuro-Behçet patients. Clin Exp Immunol. 1998; 113:100-104.
19. Aoyama J, Inaba G, Shimizu T. Third complement component in cerebrospinal fluid in neuro-Behçet's syndrome. Conversion patterns by crossed immunoelectrophoresis. J Neurol Sci. 1979;41:183-190.
20. Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H, Yavuz S, Karsli F, Yurdakul S, Yazici H, Akoglu T. Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets. J Rheumatol. 1999;26: 826-832.
21. Levinsky RJ, Lehner T. Circulating soluble immune complex in recurrent oral ulceration and Behçet's syndrome. Clin Exp Immunol. 1978;32:193-198.
22. Gamble CN, Wiesner KB, Shapiro RF, Boyer WJ. The immune complex pathogenesis of glomerulonephritis and pulmonary vasculitis in Behçet's disease. Am J Med. 1979;66: 1031-1039.
23. Braun-Falco O, Luderschmidt C, Wolff HH .The sterile Behcet pustule: a typical skin manifestation of the Behçet syndrome. Dtsch Med Wochenschr. 1983;108:820-825.
24. Versey JM, Slatter L, Hobbs JR. Activation of complement in relation to disease. J Clin Pathol Suppl. 1975;6:38-44.
25. Evans CA, Jellis J, Hukhes SP, Reinick DG, Priedland JS. Tumor necrosis factor-alpha, interleukin-6, and interleukin-8 secretion and the acute phase response in patients with bacterial and tuberculous osteomyelitis. J Infect Dis. 1998;177: 1582-1587.
26. th ed. London: Mosby, 2001.